London Marathon – Ken’s amazing feat

Just to let you know that Ken Fitzmaurice (who was running for UIG and BUS via Fight for Sight and raising money for Dr John Curnow and Professor Phil Murray who are researching the causes of uveitis) completed the course in under 4 hours (he did flag a little at the 30 km mark – he blames the heat!).

So far, he has raised just over £1,200 and our target is £2,500, so we really want to keep raising money. With this in mind, Ken has decided to run the Dublin marathon in November – so please, please dig deep and donate to this amazing cause, which may find a cure for all of us! For those of you who have donated, thank you so much.
Rea

Make sure your GP and your consultant communicate!

At BUS, we hear a lot of stories about the difficulties patients with Birdshot have in getting the right medication prescription from their GP.  Many of us with Birdshot have complicated medication regimes – the doses tend to change if we are in flare up or remission, and the actual type of medication may change quite frequently, if we are not responding to our current medication regimes. The other issue we face is that many of the medications we use come in branded and generic forms. So, for example, for those of us on cellcept, this now comes generically and many of us are now using a different brand, (for example Myfenax,) rather than Cellcept, although they are both mycophenolate mofetil. A GP may be keen to issue us with the generic form of our medication, as it is often cheaper and often just as effective. However for some types of immunosuppressants, the generic form is different and has a different effect. Your consultant and possibly your pharmacist will know this, but your GP may well not know.

Communications between the consultant and the GP is never very speedy and often we are faced with having to tell our GP ourselves that the medication regime has changed. This leaves the GP in a difficult position, as the medication regimes are quite toxic, often expensive and the GP is not an expert on immunosuppressants, although should have much more knowledge on steroids. But, do remember that the GP takes responsibility for not over-medicating us and for giving us the appropriate medication; and when we get a prescription from the GP, our medication costs (for those of us using NHS medications) come out of the GPs budget (or the budget of your local Primary Care Trust), and not the hospital. It is really, really important to make sure that you get your consultant and GP to communicate well to avoid any difficulties. One way of doing this is asking your consultant to give you a formal note that you can take to your GP which specifically states any changes in medication, the dosages and whether they need to be branded or the generic forms will do. Another way is by making sure you see the same GP each time and build a relationship with him or her.   And, of course, it is really important that we understand the medication regimes ourselves and the implications of them, so we can help guide our GP.

Just to illustrate how difficult it can be, we are sharing with you a couple of stories from our members (if anybody else has similar stories or stories about their difficulties, do let us know):

Real Ale’s story:

“Having had Neoral (Ciclosporine) added to his Cellcept, because of a flare up after his cataract operation, Real Ale went to his GP for a repeat prescription of the drug. In his efforts to save money the GP prescribed the generic form of Ciclosporine, not realising that could cause a problem. Fortunately the friendly, sharp eyed pharmacist rang Real Ale and queried whether it should be the generic form, pointing out that Ciclosporine was one of those rare drugs that once you have started with a particular brand, you should always continue with the same brand, unless you are deliberately switched. This meant that Real Ale had to go back to the Hospital pharmacy to confirm this was indeed correct. Different brands of ciclosporin have different rates of absorption of the active ingredient which is one reason for taking the drug at specific times. Real Ale’s pharmacist told him to put this advice in writing to his GP and requested a copy was sent to the pharmacy for future reference.

The second story concerns another patient with a similar issue about lack of communications. This time the dose of ciclosporin was being reduced but the GP was not informed and continued to prescribe the wrong strength. Ciclosporin capsules are not something you can break in half to take so this meant a trip back to the hospital to collect the repeat prescription as the GP refused to prescribe it, in the absence of notification from the consultant.

These stories highlight how difficult it can be to have a rare disease that fluctuates and is treated with toxic and expensive medication that is often outside of the experience of the GP. Hence the need to keep the GP properly informed, and to help guide the GP. We are also copying an article below about the pressure placed on GPs to the costs of medications they prescribe (hence the need for us to keep our GPs informed about our rare disease, its fluctuating nature and our need for different medication regimes at different times):

‘GPs are being banned from prescribing high-cost drugs approved by NICE as NHS managers seek drastic savings on prescribing budgets’.

This story was in this week’s Pulse (the professional journal for GPS). It’s about the cuts that certain PCTs are making by creating a banned drugs list to save money. It includes enteric coated prednisolone. What is really important to remember is that we have a RARE DISEASE which SHOULD fall outside of the scope of NICE (NICE is the National Institute of Clinical Excellence and decides on what medications can be used on the NHS) – for those of us with rare diseases, we SHOULD get more flexibility than the NICE guidelines – yet another reason for ensuring your consultant communicates well with your GP and that you build up very, very strong relationships with your GP, your consultant and your pharmacist. Do let us know if any of you are having problems – the more evidence we have, the more able we are to approach the ‘authorities’ such as NICE and the organisation that deals with rare diseases – AGNSS (the Advisory Group for National Specialised Services).

Rea and Annie

 

Update on Birdshot Uveitis Society.

Since the launch of the Birdshot Uveitis Society website just over a year ago, we are now in touch with over 250 people with Birdshot from across the world with nearly 100 of these people living in the UK and signed up and registered with BUS.

In addition we have people registered from as far away as away as USA, Canada, Honolulu, Fiji, Israel, New Zealand, Australia,  South Africa as well as several European countries. 25 healthcare professionals are also signed up (NOTE this does not include all of the medical people involved with the Birdshot Day). These professionals with an interest in Birdshot range from consultants, researchers, registrars, doctors, nurses, medical students, pharmacists and other allied professionals.

We believe that BUS is making strides towards our objectives, having managed to identify a significant group of people who have the condition. We believe that we are in a position to be able to provide a good cohort of patients for researchers interested in doing research into this sight threatening disease.

Annie and Rea

Important please read

Dear Members

We believe that there was a problem with our weekly newsletter last week. It would seem to have got caught up in new spam filters before it ever reached you.  Obviously we are not sure how widespread this problem was, but we thought we should email you to let you know about the potential issue.

We are told that if you add this email address to your address book, it may help prevent this from happening.  If that does not work and you still do not get the news updates,  and so that you do not miss out on any important news, you can always subscribe to the site via the RSS feed button that you find in the top right hand corner of screen.  Simply save the feed to your internet  favourites bar, as described in our post last week, and then check it from time to time to see what is new on the site.

Also please note that if you do not wish to receive our weekly update news from us, you have the option of signing into the website and unsubscribing from the news letter when you are logged in.

Yours

REA AND ANNIE

Short survey for all people with Birdshot

We would also like to gather more information about people who have birdshot and have a short questionnaire that we would like you to download, fill in and send back to us.

These questionnaires will be analysed and they will be written up for potential funding bodies such as the National Institute of Health Care Research.

Please be assured that this information will be held in strictest confidence and individual information will not be released to anyone. (aggregated, general information, will be used to further the cause of Birdshot).

BIRDSHOT QUESTIONNAIRE MARCH 2011 (word document)

BIRDSHOT QUESTIONNAIRE MARCH 2011 (pdf document)

Annie and Rea

Pilot study to explore motion perception

We wrote an introductory piece about this earlier this month and are delighted to now be able to include a short description  written by Nacima Kisma  a researcher at Moorfields who is helping consultant Mark Westcott with the study.  It helps to explain what they hope to achieve from it.

The monitoring of birdshot chorioretinopathy (BCR) cannot be done on a clinical basis only. Clinical signs are usually not immediately detectable when the disease does progress. We therefore need ancillary testing to help us with adjusting and reducing the systemic treatment as quickly as possible.

Electrodiagnosis testing (EDT) is of good value for the monitoring of the disease but does take a long time to perform and is not easy to schedule. Moreover, it can be uncomfortable because of corneal contact lenses, electrodes and flashing lights use.

Visual field testing is much easier to schedule and less uncomfortable than the EDT. The Moorfields Motion Displacement Test (MDT) is a kind of visual field test performed on a laptop. There are 32 lines displayed on a grey background. The lines do move randomly. The patient has to fixate a central spot and to click on the computer mouse when he sees a line moving.

Because it is easy to understand, quick to do (less than 2 minutes) and possible to display on a laptop, we hope that it would be of better use than the other field tests for the monitoring of the disease.

We have decided to look for abnormalities of motion perception in 20 birdshot patients from Moorfields uveitis clinics as a preliminary study. The pilot study is nearing completion and was open to Moorfields patients only.

If this study confirms motion perception losses in BCR, then we postulate that measurement of motion perception losses may be useful in monitoring the disease.

Good outcome from steroid implants

An American study was published earlier this year, looking at the outcomes for Birdshot patients who had been on steroid implants (the longer name for these steroid implants is corticosteroid intraocular devices). 22 Birdshot patients were involved in the study which looked retrospectively (over a 3 year period) at the outcomes.

The outcomes were extremely positive, and showed that the steroid implants had significantly improved vision, controlled inflammation and in the majority of cases stopped the need for other medications. As always, there are some down sides – in the case of steroid implants the main side effects were a high incidence of the progression of cataracts and a high incidence of intraocular pressure (called glaucoma).

If you want to read the full study, go to the American Journal of Ophthalmology.

We at BUS, are really excited that there seems to be a growing number of suitable alternatives for people who are not responding well to oral steroids and various different types of immunosuppressants, or who cannot tolerate these medication regimes.

The importance of a published study is that it provides evidence for patients and consultants who might be struggling to acquire steroid implants from their primary care trusts or health organisation, or who are looking for alternatives to oral steroids and immunosuppression.

For those of you who attended the Birdshot Day in September 2010, you will remember that steroid implants were discussed at some length on the Day. There was one attendee who had these implants and was extremely passionate about them.

If you want to hear more about steroid implants for the Birdshot Day, please go to our clip on retisert implants at:

Since the Birdshot Day, we have heard from one attendee who says that the Day changes her life and equipped her with enough information to be confident in moving to steroid implants. She reports that she can now see clearly for the first time for many years without the aid of immunosuppressive treatment. We also know of another person who has been offered them on a special trial and a third person who is discussing this option with their specialist.

We are so pleased at the more rapid progress of alternative treatments and we are delighted that the Birdshot Day has equipped attendees with the means to work in partnership with their consultants to explore all possible options. We are even more delighted to see that so many more consultants are now listening to their patients and there is a two way dialogue and a real exploration of all options available. Let’s hope that we can also make some headway in finding out the reason we get Birdshot in the first place!

What is an RSS feed?

rss feed graphic

Have you ever wondered what that orange button in the top right hand corner of our website was for?

It’s a news feed button, which if you click and subscribe to keeps you in touch with recent news.  You can get the latest headlines in one place, as soon as it’s published, without having to visit the websites you have taken the feed from, eg on our website it takes you to here:    feed://birdshot.org.uk/index.php/feed . It also provides an easy way of scrolling though previous topics if you are trying to find a post but are not sure where to look.

How do I start using feeds?

You will need one of the following to read RSS feeds:

Modern web browser or a web news reader

Most modern browsers, including Firefox, Opera, Internet Explorer, Safari and Chrome automatically check for feeds when you visit a website, and display the orange RSS icon when they find one. Many of them allow you to add RSS feeds as a browser favourite or bookmark folder, automatically updating them with the latest content.

There is a range of different news readers available and new versions are appearing all the time.  Different news readers work on different operating systems, so you will need to choose one that will work with your computer  Once you have chosen a news reader, all you have to do is to decide what content you want it to receive.

For example, on the case of Birdshot Uveitis Society,  simply visit our website and select the orange RSS button on your browser, and add  it to your favourite websites.

Bringing Together Patients and Specialists

This is the abstract for the poster that trainee ophthalmologist Nik Koutroumanos presented at the London, Kent, Surrey and Sussex Deanery Trainees conference last week.  It describes what happened at the Birdshot Day  and it caused quite a lot of interest there among the young doctors  who will have gone away from the conference much more aware about our particular rare condition.  There is great  value in educating future ophthalmologists, who are not yet commited to a subspecialty area of uveitis and who will be carrying the knowledge of Birdshot to the corneal, vitreoretinal and paediatric eye clinics that they will inevitably become involved in. Thanks Nik for helping to spread the word.

Purpose: Birdshot Chorioretinopathy (BCR) is a rare, chronic, poorly understood, bilateral posterior uveitis, which results in loss of visual function. The disease and its treatment have dire effects on quality of life. The aims of the project were 5 fold: 1) To reduce the sense of isolation of patients with BCR, 2) to raise the profile of the disease 3) to allow a two-way exchange of information between patients and professionals, 4) to obtain a better visual outcome and 5) to provide a base for research.

Methods: A Birdshot Day was organized by founders of the Birdshot Uveitis Society along with a team of healthcare professionals, public-engagement and audio-visual specialists. What patients wanted was the focus of the team’s efforts. The event allowed for extensive networking and exchange of ideas, talks by specialists and patient representatives and ‘Question & Answer’ sessions which addressed patients’ concerns. Structured anonymised questionnaires and formal interactive evaluation techniques were used to fully evaluate the success and short and long term impact of the day on both patients and professionals.

Results: 50 Patients & 26 supporters joined 50 healthcare professionals for the Patient Day. Data analysis demonstrated a significant improvement in patient knowledge (P<0.001). Results showed that the priorities of patients and clinicians were not necessarily the same. Whilst drug side-effects were deemed the major problem in terms of patients’ quality of life (55.8%), BCR patients prioritised research into aetiology (47.8%) in preference to research into better medication (31.8%). There was evidence that patients greatly valued meeting fellow sufferers (P<0.001). Results strongly suggested that patients’ sense of isolation was significantly reduced and the number of ‘hits’ on the BUS website in the 3-weeks following more than doubled to 67,000. To date, 4 of our 5 aims have been achieved.

Conclusions: We believe that this level of patient engagement should be encouraged. The Birdshot Patient Day proved a success. It has led to better understanding between patients and professionals. Patients have successfully directed and engaged into future research into their condition and future Birdshot Patient days are planned.

After the conference , Nik told us that  he found that many trainees  at the conference were  greatly interested in the concept of a patient day for a rare condition and he  also thought that it was most valuable to  be able talk to trainee ophthalmologists about the significance of involving patients  in research.

We look forward to results.

Stem cell therapy may well restore sight

http://www.telegraph.co.uk/health/healthnews/8376433/Stem-cell-injection-reverses-glaucoma.html

The link above takes you to an article on how stem therapy might be able to help people with glaucoma in the future.

Rea and I are not experts on this, but we are assuming that if stem cell therapy can grow retinal cells for people with glaucoma, the same could be true for people with Birdshot.

It’s a “brave new world” development and we need to monitor and watch this development closely.  It could give hope to people with sight loss who, until now, thought there was nothing that could be done.

The Cambridge scientist and ophthalmologist involved in the research, Professor Keith Martin said:-

“We are doing it in animal models and results are so encouraging that we hope to move forward to testing on humans soon.

Stem cell treatment is moving forward very fast in many branches of the medicine and we are seeing some of the best results in eyes.”

He added: “We have concentrated on glaucoma because it is so common, but there are quite a few diseases that affect the optic nerve, such as inflammatory diseases, so it could be used here too.”

As we all know Birdshot Chorioretinopathy is an inflammatory disease of the eye. We don’t know how long these developments will take to progress, but we live in a fast moving world and it gives us hope.

This research has received funding from Fight for the Sight, a charity that raises money for research into sight threatening conditions.  We have a runner running for us in the London Marathon in aid of Uveitis Research that Fight for Sight is also supporting and if you want to make a donation towards this project you can do so at Ken’s Just Giving page. http://www.justgiving.com/Kenneth-Fitzmaurice

Annie and Rea